Cue in pact with Boehringer for autoimmune and inflammatory diseases
Source: SeekingAlpha
2025-04-15 08:00:13 ET
More on Cue Biopharma
- Cue Biopharma stock falls after pricing capital raise of $20M via securities offering
- Seeking Alpha’s Quant Rating on Cue Biopharma
- Historical earnings data for Cue Biopharma
- Financial information for Cue Biopharma
Read the full article on Seeking Alpha
For further details see:
Cue in pact with Boehringer for autoimmune and inflammatory diseases
Cue Biopharma Inc.
NASDAQ: CUE
CUE Trading
-4.44% G/L:
$0.31 Last:
1,055,945 Volume:
$0.309 Open:
CUE Latest News
March 09, 2026 08:00:00 am
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
February 17, 2026 08:00:00 am
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
February 12, 2026 08:00:00 am
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
CUE Stock Data
$30,117,989
80,549,371
0.16%
23
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
